A study of the level of vascular endothelial growth factor and basic fibroblast growth factor in combined treatment of patients with stage III non-small cell lung cancer using neoadjuvant chemotherapy and surgery
Vol. 60 No. 6 (2014), Articles
Vol. 60 No. 6 (2014)

A study of the level of vascular endothelial growth factor and basic fibroblast growth factor in combined treatment of patients with stage III non-small cell lung cancer using neoadjuvant chemotherapy and surgery

Articles
https://doi.org/10.37469/0507-3758-2014-60-6-741-744
Published 15.12.2014
Regional Clinical Oncology Dispensary
Regional Clinical Oncology Dispensary
State Medical University
N.N. Petrov Research Institute of Oncology
Regional Clinical Oncology Dispensary
Regional Clinical Oncology Dispensary
N.N. Petrov Research Institute of Oncology
##article.numberofdownloads## 19
##article.numberofviews## 53
PDF (Русский)

Keywords

non-small cell lung cancer (NSCLC)
vascular endothelial growth factor (VEGF)
basic fibroblast growth factor (BFGF)
neoadjuvant chemotherapy

How to Cite

, , , , , , & . (2014). A study of the level of vascular endothelial growth factor and basic fibroblast growth factor in combined treatment of patients with stage III non-small cell lung cancer using neoadjuvant chemotherapy and surgery. Voprosy Onkologii, 60(6), 741–744. https://doi.org/10.37469/0507-3758-2014-60-6-741-744
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

There were examined 198 patients with non-small cell lung cancer (NSCLC). The levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (BFGF) as predictors at using neoadjuvant chemotherapy in patients with NSCLC were studied. Determination of baseline levels of VEGF and BFGF were necessary to predict the combination treatment of patients with stage III NSCLC.
https://doi.org/10.37469/0507-3758-2014-60-6-741-744
##article.numberofdownloads## 19
##article.numberofviews## 53
PDF (Русский)

References

Миллер С.В., Тузиков С.А., Гольдберг В.Е. и др. Неоадъювантная химиотерапия в комбинированном лечении немелкоклеточного рака легкого // Росс. онкол. журнал. - 2009. - № 2. - С. 31-34.

Полежаев А.А., Ступина С.В., Булатова О.Н. Опыт комбинированного лечения немелкоклеточного рака легкого с применением неоадъювантной полихимиотерапии // Росс. онкол. журнал. - 2008. - № 4. - С. 31-35.

Трахтенберг А.Х., Колбанов К.И. Рак легкого // Под ред. В.И. Чиссова. - М.: ГЭОТАР-Медиа. - 2014. - 160 с.

Andre F., Grunenwald D., Pignon J.P. et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassifi cation and implications // J. Clin. Oncol. - 2000. - Vol. 18. - Р. 2981-2989.

Berghmans T., Paesmans M., Meert A.P. et al. Survival improvement in resectable non-small cell lung cancer with (neo) adjuvant chemotherapy: results of a meta-analysis of the literature // Lung Cancer. - 2005. - Vol. 49. - Р. 3-23.

Burdett S., Stewart L.A., Rydzewska L. A systematic review and metaanalysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer // J. Thorac. Oncol. - 2006. - Vol. 1. - Р. 611-621.

Eriksson P., Brattstrom D., Hesselius P. et al. Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curativeli intended treatment // Neoplasma. - 2006. - Vol. 53(4). - P. 285-290.

Iwasaki A., Kuwahara M., Yoshinaga Y. et al. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognosis indicators in NSCLC // Eur. J. Cardiothorac. Susg. - 2004. - Vol. 25 (3). - P. 442-448.

Linderholm B., Grankvist K., Wilking N. et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary nodepositive breast carcinoma after adjuvant treatment // J. Clin. Oncol. - 2000. -Vol. 18. - P. 1423-1431.

Lund E., Thorsen C., Petersen M.et al. Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro // Clinical Cancer Research.- 2000. - Vol. 6. - P. 4287-4291.

Matsuyama W., Hashiguchi T., Mizoguchi A. et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer // Chest. - 2000. - Vol. 118. - P. 948-951.

K.A. Olaussen, A. Dunant, P. Fouret et al. DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy // New Engl. J. Med. - 2006. - Vol. 355. - Р. 983-991.

Renouf D.J., Wood-Baker R., Ionescu D.N. et al. BCL-2 Expression is Prognostic for Improved Survival in Nonsmall Cell Lung Cancer // J. Thorac. Oncol. - Vol. 4. - N. 4. - Р. 486-491.

Rosell R., Boukovinas I., Papadaki C. et al. Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients // PLOS One. - 2008. - Vol. 3 (11). - e3695.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...